5 Healthcare Stocks Billionaires Love The Most

Gilead Sciences, Inc. (NASDAQ:GILD)

13 billionaires amassed Gilead Sciences, Inc. (NASDAQ:GILD) shares at the end of the September quarter, compared to 12 billionaires a quarter earlier. The total value of these shares was worth $1.22 billion. Gilead Sciences, Inc. (NASDAQ:GILD) is reportedly considering increasing its M&A activity given its large cash pile and potential activist pressure if management doesn’t ramp up its growth/value results. At the end of the third quarter, 87 hedge funds tracked by Insider Monkey were bullish on Gilead Sciences, Inc. (NASDAQ:GILD).

Humana Inc (NYSE:HUM)

12 out of 64 billionaires in our data were long Humana Inc (NYSE:HUM) at the end of the third quarter. Those ultra-net worth investors owned 2.89 billion worth of the company’s shares in aggregate. Humana was recently upgraded by Credit Suisse to ‘Outperform’ from ‘Neutral’ with a price target of $210 from $175. Susquehanna increased its price target for the company to $200 per share after Humana’s third quarter results, in which the company earned third quarter EPS of $3.18 on $13.69 billion revenue, while analysts expected EPS of $3.09 and $13.41 billion revenue. For full year, the company expects EPS of $9.50, versus the consensus of $9.51. Larry Robbins’ Glenview Capital owns 9.53 million shares of Humana Inc (NYSE:HUM) as of the end of Q3.

Biogen Inc (NASDAQ:BIIB)

At the end of the third quarter, 12 billionaires tracked by Insider Monkey had amassed $2.18 billion worth of shares of Biogen Inc (NASDAQ:BIIB), compared to 11 funds a quarter earlier. Biogen shares were recently rattled after the Indiana-based Eli Lilly and Company recently said its Alzheimer’s Disease drug Solanezumab missed a primary endpoint of slowing cognitive decline in a study. Biogen is working on a drug that targets a similar market as Eli Lilly. Leerink analyst Geoffrey Porges slashed Biogen’s price target to $355 from $365.00 after Lilly’s announcement. Out of 742 funds tracked by Insider Monkey, 81 were bullish on Biogen Inc (NASDAQ:BIIB), versus 73 funds long the stock a quarter earlier.

Disclosure: None